4 recap points by Dr. Arnas Karužas on European Society of Cardiology Congress in London:
1) There is exponential growth in trials with AI. Importantly, these innovations are being implemented into daily practice.
2) New guidelines for atrial fibrillation management were introduced. They offer a fresh approach to evaluating thromboembolism risk. The CHA2DS2VASc score no longer includes sex. The new recommendation is to use the CHA2DS2 VA score.
3) For atrial fibrillation lasting more than 24 hours, specific protocols are advised. Three weeks of oral anticoagulation or a transesophageal echocardiogram is recommended before cardioversion.
4) guidelines have been updated. They now provide a new estimation of risk factor-weighted clinical likelihood for obstructive CAD. This change addresses the previous overestimation issues with obstructive CAD.
Echocardiography software is part of the bigger AI transformation in cardiology. Ligence is proud to be shaping medical history.
The implementation of these new guidelines highlights the need for precision and consistency in echocardiographic assessments. Advanced echocardiography software, like the solutions offered by Ligence, can play a crucial role in ensuring that strain analysis and LV diastolic function measurements adhere to the latest standards. By integrating cutting-edge software into your practice, you can enhance diagnostic accuracy and improve patient outcomes.
Disclaimer: Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
